

# TAVNEOS

## PRIOR AUTHORIZATION REQUEST

### PRESCRIBER FAX FORM

**Only the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews.**

The following documentation is **REQUIRED**. Incomplete forms will be returned for additional information. For formulary information please visit [www.myprime.com](http://www.myprime.com). Start saving time today by filling out this form electronically. Visit [covermymeds.com](http://covermymeds.com) to begin using this free service.

**What is the priority level of this request?**

- Standard review
- Expedited/Urgent review – prescriber certifies that waiting for a standard review could seriously harm the patient's life, health or ability to regain maximum function

**Today's Date:** \_\_\_\_\_

**PATIENT AND INSURANCE INFORMATION**

**Date of Service (if differs from Today's Date):** \_\_\_\_\_

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
Patient Address:	City, State, Zip:	Patient Telephone:	
Member ID Number:	Group Number:		

**PRESCRIBER/CLINIC INFORMATION**

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:	Clinic Address:		
City, State, Zip:	Phone #:	Secure Fax #:	

**PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST**

Patient's Diagnosis:

- Severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and/or microscopic polyangiitis [MPA])?
- Other (ICD code plus description): \_\_\_\_\_

Medication Requested:	Strength:
Dosing Schedule:	Quantity per Month:

**For all requests:**

- Is the patient currently treated with the requested agent? .....  Yes  No  
 If yes, was the treatment started on samples? .....  Yes  No  
 If yes, is the patient at risk if therapy is changed? .....  Yes  No  
 If yes, please explain risk: \_\_\_\_\_
- Does the patient have any FDA labeled contraindications to the requested agent? .....  Yes  No  
 If yes, please specify contraindication(s): \_\_\_\_\_
- Is the patient's age within FDA labeling for the requested indication for the requested agent? .....  Yes  No  
 If yes, please provide support for using the requested agent for the patient's age for the requested indication: \_\_\_\_\_
- Does the patient have severe hepatic impairment (Child-Pugh C)? .....  Yes  No
- Is the prescriber a specialist in the area of the patient's diagnosis (e.g., rheumatologist), or has the prescriber consulted with a specialist in the area of the patient's diagnosis? .....  Yes  No
- Has the patient been screened for prior or current hepatitis B infection? .....  Yes  No  
 If yes, were the results positive or negative? .....  Yes  No  
 If yes, has a prescriber specializing in hepatitis B treatment been consulted? .....  Yes  No

**Please continue to the next page.**

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
<p>7. Please list all reasons for selecting the requested agent for the indicated diagnosis, strength, dosing schedule, and quantity over alternatives (e.g., compendia support, journal articles, contraindications, allergies, history of adverse drug reactions to alternatives, lower dose has been tried, information supporting dose over FDA max). <b>Please note, documentation may be required:</b> _____</p> <p>_____</p> <p>_____</p>			
<b>For active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis requests:</b>			
<p>8. Has the patient had a positive ANCA-test?..... <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>9. Is the patient currently treated with standard therapy (e.g., azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab) for the requested indication? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p style="padding-left: 20px;">If yes, please specify: _____</p> <p style="padding-left: 20px;">If yes, will the patient continue standard therapy (e.g., azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab) in combination with the requested agent for the requested indication?..... <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p style="padding-left: 20px;">If yes, please specify: _____</p>			
<b>For renewal requests:</b>			
<p>10. Has the patient had clinical benefit with the requested agent? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No</p>			
<p><b>Please fax or mail this form to:</b>  Prime Therapeutics LLC  Clinical Review Department  2900 Ames Crossing Road Suite 200  Eagan, MN 55121</p> <p><b>TOLL FREE</b></p>		<p><b>CONFIDENTIALITY NOTICE:</b> This communication is intended only for the use of the individual entity to which it is addressed, and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.</p>	
<p><b>Phone:</b>  <b>BCBSIL: 800.285.9426</b>  <b>BCBSMT: 888.723.7443</b>  <b>BCBSNM: 800.544.1378</b>  <b>BCBSOK: 800.991.5643</b>  <b>BCBSTX: 800.289.1525</b></p>		<p><b>Fax: 877.243.6930</b></p>	